在胃肠道出血后重新开始抗凝和抗血小板治疗:系统性审查
Ethan Slouha1, Haley Jensen1, Hope Fozo1
1St George's University School of Medicine, Saint George's, Saint George, Grenada.
F1000Research
|July 5, 2024
概括
在胃肠道出血 (GIB) 后恢复抗凝药非常重要. 重启治疗的最佳时间是GIB后15-30天,以预防血栓事件.
科学领域:
- 胃肠病学 胃肠病学
- 心脏病学 心脏病学
- 内部医学 内部医学
背景情况:
- 胃肠道出血 (GIB) 导致显著的死亡率,上部GIB每年导致20,000名美国人死亡.
- 服用抗血栓剂的患者有4%的GIB风险,这使治疗决策复杂化.
- 风险分层对于管理GIB后的患者至关重要,特别是在抗血栓治疗方面.
研究的目的:
- 系统地审查和评估在上部胃肠道出血后恢复抗凝药时间的一般趋势.
- 为在GIB后需要抗血栓治疗的患者提供临床决策信息.
主要方法:
- 在PubMed,ScienceDirect和ProQuest进行了系统的文献搜索,由三位独立审稿人进行.
- 文章使用特定的包含和排除标准进行了选.
- 总共有11,769篇文章最初被确定,最终有22篇被纳入审查中.
主要成果:
- 在GIB后恢复抗凝药与血栓事件的风险降低有关.
- 恢复抗凝固药物治疗的最佳时间框架被确定为GIB后15-30天.
- 延迟抗凝剂增加了血栓栓塞并发症的风险.
结论:
- 在GIB后恢复抗凝血治疗的决定需要仔细考虑个体患者的因素和病史.
- 建议在15-30天窗口内恢复治疗,以平衡出血和血栓风险.
- 本系统性审查提供了基于证据的指导,用于管理有上部GIB病史的患者的抗凝血治疗.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
514
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
514
Anticoagulant Drugs: Low-Molecular-Weight Heparins
672
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
672
Esophageal Varices-II: Clinical Features and Management
57
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
57
Introduction to Hemostasis
7.1K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.1K
Disorders of Hemostasis
824
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
824


